Carlos Villa Joins Versiti Blood Research Institute
Versiti Blood Research Institute shared on LinkedIn:
”Please welcome Carlos Villa, MD, PhD to VBRI!
Carlos Villa is joining the Translational Hematology Program as a Transfusion Medicine Clinician Investigator.
He joins Versiti from the US Food and Drug Administration where, most recently, he was the Associate Director for Special Programs in the Office of Blood Research and Review at CBER.
In that role, he contributed to regulatory, policy, and research initiatives to advance the safety and effectiveness of blood and blood components.
His clinical background is in Clinical Pathology and Transfusion Medicine, and his research has spanned basic sciences to clinical medicine, with experience in pharmacology and drug delivery.
He completed his MD/PhD training at the Tri Institutional program at Weill Cornell and Memorial Sloan Kettering, which was followed by residency and fellowship training at the University of Pennsylvania.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’